Kuffner E K, Green J L, Bogdan G M, Knox P C, Palmer R B, Heard K, Slattery J T, Dart R C
Rocky Mountain Poison & Drug Center, Denver Health, Denver, CO, USA.
BMC Med. 2007 May 30;5:13. doi: 10.1186/1741-7015-5-13.
Hepatic failure has been associated with reported therapeutic use of acetaminophen by alcoholic patients. The highest risk period for alcoholic patients is immediately after discontinuation of alcohol intake. This period exhibits the largest increase in CYP2E1 induction and lowest glutathione levels. Our hypothesis was that common liver tests would be unaffected by administration of the maximum recommended daily dosage of acetaminophen for 3 consecutive days to newly-abstinent alcoholic subjects.
Adult alcoholic subjects entering two alcohol detoxification centers were enrolled in a prospective double-blind, randomized, placebo-controlled trial. Subjects were randomized to acetaminophen, 4 g/day, or placebo for 3 consecutive days. The study had 95% probability of detecting a 15 IU/L difference in serum ALT.
A total of 443 subjects were enrolled: 308 (258 completed) received acetaminophen and 135 subjects (114 completed) received placebo. Study groups did not differ in demographics, alcohol consumption, nutritional status or baseline laboratory assessments. The peak mean ALT activity was 57 +/- 45 IU/L and 55 +/- 48 IU/L in the acetaminophen and placebo groups, respectively. Subgroup analyses for subjects presenting with an elevated ALT, subjects fulfilling a diagnosis of alcoholic hepatitis and subjects attaining a peak ALT greater than 200 IU/L showed no statistical difference between the acetaminophen and control groups. The one participant developing an increased international normalized ratio was in the placebo group.
Alcoholic patients treated with the maximum recommended daily dose of acetaminophen for 3 consecutive days did not develop increases in serum transaminase or other measures of liver injury. Treatment of pain or fever for 3 days with acetaminophen appears safe in newly-abstinent alcoholic patients, such as those presenting for acute medical care.
据报道,酒精性肝病患者使用对乙酰氨基酚进行治疗会引发肝衰竭。酒精性肝病患者的最高风险期是在停止饮酒后即刻。此期间CYP2E1诱导作用增强最为明显,谷胱甘肽水平降至最低。我们的假设是,连续3天给予新近戒酒的酒精性肝病受试者最大推荐日剂量的对乙酰氨基酚,常规肝功能检查不会受到影响。
进入两家戒酒中心的成年酒精性肝病受试者参与了一项前瞻性双盲、随机、安慰剂对照试验。受试者被随机分为连续3天服用4克/天对乙酰氨基酚组或安慰剂组。该研究有95%的概率检测出血清ALT水平有15 IU/L的差异。
总共招募了443名受试者:308名(258名完成试验)接受对乙酰氨基酚治疗,135名受试者(114名完成试验)接受安慰剂治疗。研究组在人口统计学、饮酒量、营养状况或基线实验室评估方面无差异。对乙酰氨基酚组和安慰剂组的平均ALT活性峰值分别为57±45 IU/L和55±48 IU/L。对ALT升高的受试者、符合酒精性肝炎诊断标准的受试者以及ALT峰值大于200 IU/L的受试者进行亚组分析,结果显示对乙酰氨基酚组和对照组之间无统计学差异。国际标准化比值升高的1名受试者在安慰剂组。
连续3天接受最大推荐日剂量对乙酰氨基酚治疗的酒精性肝病患者,血清转氨酶或其他肝损伤指标并未升高。对新近戒酒的酒精性肝病患者,如因急性医疗需求前来就诊的患者,使用对乙酰氨基酚治疗3天的疼痛或发热症状似乎是安全的。